2
|
Orsi D, Pook E, Bräuer N, Friberg A, Lienau P, Lemke CT, Stellfeld T, Brüggemeier U, Pütter V, Meyer H, Baco M, Tang S, Cherniack AD, Westlake L, Bender SA, Kocak M, Strathdee CA, Meyerson M, Eis K, Goldstein JT. Discovery and Structure-Based Design of Potent Covalent PPARγ Inverse-Agonists BAY-4931 and BAY-0069. J Med Chem 2022; 65:14843-14863. [PMID: 36270630 PMCID: PMC9662185 DOI: 10.1021/acs.jmedchem.2c01379] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2022] [Indexed: 11/29/2022]
Abstract
The ligand-activated nuclear receptor peroxisome-proliferator-activated receptor-γ (PPARG or PPARγ) represents a potential target for a new generation of cancer therapeutics, especially in muscle-invasive luminal bladder cancer where PPARγ is a critical lineage driver. Here we disclose the discovery of a series of chloro-nitro-arene covalent inverse-agonists of PPARγ that exploit a benzoxazole core to improve interactions with corepressors NCOR1 and NCOR2. In vitro treatment of sensitive cell lines with these compounds results in the robust regulation of PPARγ target genes and antiproliferative effects. Despite their imperfect physicochemical properties, the compounds showed modest pharmacodynamic target regulation in vivo. Improvements to the in vitro potency and efficacy of BAY-4931 and BAY-0069 compared to those of previously described PPARγ inverse-agonists show that these compounds are novel tools for probing the in vitro biology of PPARγ inverse-agonism.
Collapse
Affiliation(s)
- Douglas
L. Orsi
- Center
for the Development of Therapeutics, Broad
Institute of MIT and Harvard, Cambridge, Massachusetts 02142, United States
| | - Elisabeth Pook
- Research
and Development, Pharmaceuticals, Bayer
AG, 13353 Berlin, Germany
| | | | | | - Philip Lienau
- Research
and Development, Pharmaceuticals, Bayer
AG, 13353 Berlin, Germany
| | - Christopher T. Lemke
- Center
for the Development of Therapeutics, Broad
Institute of MIT and Harvard, Cambridge, Massachusetts 02142, United States
| | | | - Ulf Brüggemeier
- Research
and Development, Pharmaceuticals, Bayer
AG, 13353 Berlin, Germany
| | | | | | - Maria Baco
- Cancer
Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, United States
| | - Stephanie Tang
- Cancer
Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, United States
| | - Andrew D. Cherniack
- Cancer
Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, United States
- Department
of Medical Oncology, Dana-Farber Cancer
Institute, Boston, Massachusetts 02215, United States
| | - Lindsay Westlake
- Cancer
Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, United States
| | - Samantha A. Bender
- Cancer
Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, United States
| | - Mustafa Kocak
- Cancer
Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, United States
| | - Craig A. Strathdee
- Cancer
Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, United States
| | - Matthew Meyerson
- Cancer
Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, United States
- Department
of Medical Oncology, Dana-Farber Cancer
Institute, Boston, Massachusetts 02215, United States
- Center for
Cancer Genomics, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, United States
- Department
of Genetics and Medicine, Harvard Medical
School, Boston, Massachusetts 02115, United States
| | - Knut Eis
- Research
and Development, Pharmaceuticals, Bayer
AG, 13353 Berlin, Germany
| | - Jonathan T. Goldstein
- Cancer
Program, Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, United States
| |
Collapse
|
3
|
Huang FW, Mosquera JM, Garofalo A, Oh C, Baco M, Amin-Mansour A, Rabasha B, Bahl S, Mullane SA, Robinson BD, Aldubayan S, Khani F, Karir B, Kim E, Chimene-Weiss J, Hofree M, Romanel A, Osborne JR, Kim JW, Azabdaftari G, Woloszynska-Read A, Sfanos K, De Marzo AM, Demichelis F, Gabriel S, Van Allen EM, Mesirov J, Tamayo P, Rubin MA, Powell IJ, Garraway LA. Exome Sequencing of African-American Prostate Cancer Reveals Loss-of-Function ERF Mutations. Cancer Discov 2017; 7:973-983. [PMID: 28515055 PMCID: PMC5836784 DOI: 10.1158/2159-8290.cd-16-0960] [Citation(s) in RCA: 86] [Impact Index Per Article: 12.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2016] [Revised: 02/22/2017] [Accepted: 05/04/2017] [Indexed: 12/25/2022]
Abstract
African-American men have the highest incidence of and mortality from prostate cancer. Whether a biological basis exists for this disparity remains unclear. Exome sequencing (n = 102) and targeted validation (n = 90) of localized primary hormone-naïve prostate cancer in African-American men identified several gene mutations not previously observed in this context, including recurrent loss-of-function mutations in ERF, an ETS transcriptional repressor, in 5% of cases. Analysis of existing prostate cancer cohorts revealed ERF deletions in 3% of primary prostate cancers and mutations or deletions in ERF in 3% to 5% of lethal castration-resistant prostate cancers. Knockdown of ERF confers increased anchorage-independent growth and generates a gene expression signature associated with oncogenic ETS activation and androgen signaling. Together, these results suggest that ERF is a prostate cancer tumor-suppressor gene. More generally, our findings support the application of systematic cancer genomic characterization in settings of broader ancestral diversity to enhance discovery and, eventually, therapeutic applications.Significance: Systematic genomic sequencing of prostate cancer in African-American men revealed new insights into prostate cancer, including the identification of ERF as a prostate cancer gene; somatic copy-number alteration differences; and uncommon PIK3CA and PTEN alterations. This study highlights the importance of inclusion of underrepresented minorities in cancer sequencing studies. Cancer Discov; 7(9); 973-83. ©2017 AACR.This article is highlighted in the In This Issue feature, p. 920.
Collapse
Affiliation(s)
- Franklin W Huang
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
- Department of Medicine, Harvard Medical School, Boston, Massachusetts
- Cancer Program, the Broad Institute of Harvard and MIT, Cambridge, Massachusetts
| | - Juan Miguel Mosquera
- Caryl and Israel Englander Institute for Precision Medicine, Weill Cornell Medicine-New York Presbyterian, New York, New York
- Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, New York
| | - Andrea Garofalo
- Cancer Program, the Broad Institute of Harvard and MIT, Cambridge, Massachusetts
| | - Coyin Oh
- Cancer Program, the Broad Institute of Harvard and MIT, Cambridge, Massachusetts
| | - Maria Baco
- Cancer Program, the Broad Institute of Harvard and MIT, Cambridge, Massachusetts
| | - Ali Amin-Mansour
- Cancer Program, the Broad Institute of Harvard and MIT, Cambridge, Massachusetts
| | - Bokang Rabasha
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
- Cancer Program, the Broad Institute of Harvard and MIT, Cambridge, Massachusetts
| | - Samira Bahl
- Cancer Program, the Broad Institute of Harvard and MIT, Cambridge, Massachusetts
| | - Stephanie A Mullane
- Cancer Program, the Broad Institute of Harvard and MIT, Cambridge, Massachusetts
| | - Brian D Robinson
- Caryl and Israel Englander Institute for Precision Medicine, Weill Cornell Medicine-New York Presbyterian, New York, New York
- Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, New York
| | - Saud Aldubayan
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
- Cancer Program, the Broad Institute of Harvard and MIT, Cambridge, Massachusetts
| | - Francesca Khani
- Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, New York
| | - Beerinder Karir
- Caryl and Israel Englander Institute for Precision Medicine, Weill Cornell Medicine-New York Presbyterian, New York, New York
- Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, New York
| | - Eejung Kim
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
- Cancer Program, the Broad Institute of Harvard and MIT, Cambridge, Massachusetts
| | - Jeremy Chimene-Weiss
- Cancer Program, the Broad Institute of Harvard and MIT, Cambridge, Massachusetts
| | - Matan Hofree
- Cancer Program, the Broad Institute of Harvard and MIT, Cambridge, Massachusetts
| | | | - Joseph R Osborne
- Centre for Integrative Biology, University of Trento, Trento, Italy
- Department of Radiology, Weill Cornell Medicine, New York, New York
| | - Jong Wook Kim
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
- Cancer Program, the Broad Institute of Harvard and MIT, Cambridge, Massachusetts
| | - Gissou Azabdaftari
- Department of Pathology, Roswell Park Cancer Institute, Roswell Park, New York
| | - Anna Woloszynska-Read
- Department of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Roswell Park, New York
| | - Karen Sfanos
- Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland
- Department of Urology, James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland
| | - Angelo M De Marzo
- Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland
- Department of Urology, James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland
| | - Francesca Demichelis
- Caryl and Israel Englander Institute for Precision Medicine, Weill Cornell Medicine-New York Presbyterian, New York, New York
- Centre for Integrative Biology, University of Trento, Trento, Italy
| | - Stacey Gabriel
- Cancer Program, the Broad Institute of Harvard and MIT, Cambridge, Massachusetts
| | - Eliezer M Van Allen
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
- Department of Medicine, Harvard Medical School, Boston, Massachusetts
- Cancer Program, the Broad Institute of Harvard and MIT, Cambridge, Massachusetts
| | - Jill Mesirov
- Cancer Program, the Broad Institute of Harvard and MIT, Cambridge, Massachusetts
- Department of Medicine, University of California, San Diego, La Jolla, California
- Moores Cancer Center, University of California, San Diego, La Jolla, California
| | - Pablo Tamayo
- Cancer Program, the Broad Institute of Harvard and MIT, Cambridge, Massachusetts
- Department of Medicine, University of California, San Diego, La Jolla, California
- Moores Cancer Center, University of California, San Diego, La Jolla, California
| | - Mark A Rubin
- Caryl and Israel Englander Institute for Precision Medicine, Weill Cornell Medicine-New York Presbyterian, New York, New York.
- Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, New York
- Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine, New York, New York
| | - Isaac J Powell
- Barbara Ann Karmanos Cancer Institute, Detroit, Michigan.
- Department of Urology, Wayne State University School of Medicine, Detroit, Michigan
| | - Levi A Garraway
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
- Department of Medicine, Harvard Medical School, Boston, Massachusetts
- Cancer Program, the Broad Institute of Harvard and MIT, Cambridge, Massachusetts
| |
Collapse
|